1. Home
  2. SUNS vs PYXS Comparison

SUNS vs PYXS Comparison

Compare SUNS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$8.35

Market Cap

109.2M

Sector

Real Estate

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$2.13

Market Cap

124.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNS
PYXS
Founded
2023
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.2M
124.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SUNS
PYXS
Price
$8.35
$2.13
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$8.75
$7.00
AVG Volume (30 Days)
74.5K
474.8K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
16.17%
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
$70.81
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
$8.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$0.97
52 Week High
$11.78
$5.55

Technical Indicators

Market Signals
Indicator
SUNS
PYXS
Relative Strength Index (RSI) 46.98 62.76
Support Level $7.39 $2.03
Resistance Level $9.69 $2.17
Average True Range (ATR) 0.30 0.16
MACD -0.05 0.04
Stochastic Oscillator 0.00 91.41

Price Performance

Historical Comparison
SUNS
PYXS

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: